Cannabis Science Releases Second Cannabis-Extract-Based Formulation Available Now at Marisol Therapeutics, 922 Kimble Drive, Pueblo West, Colorado

November 23, 2011

DENVER (BUSINESS WIRE) -- Cannabis Science, Inc. (OTCBB; CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the successful release of the second Cannabis Science brand formulation. The Company has been receiving a constant flow of inquires via its website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer patients seeking extract-based formulations for topical or internal use have frequently contacted Cannabis Science. Manufacturing and packaging has been completed and is now available through Marisol Therapeutics for patient usage.

PHONE: 719-547-4000

ADDRESS: 922 Kimble Drive Pueblo West, CO 81007

EMAIL: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

In light of the accumulating anecdotal reports of the successful cancer treatments with cannabis extracts, the Company will continue to keep patients updated on current peer-reviewed scientific literature supporting the historical and modern use of cannabis to treat "tumors". Unlike conventional treatment, cannabis medicines have an outstanding safety profile allowing patients in states with medical marijuana laws to safely make informed decisions to legally self-administration of various cannabis-based preparations.

The second Cannabis Science Brand extract-based formulation is comprised of high quality extract packaged in oral dispensing syringes for patient self-administration for treatment. This is a critical milestone for the Company in bringing its second formulation to market. Other formulations will be made available soon to medical marijuana patients in Colorado and around the world through the Company's vetted dispensaries. The Company's intent is to work with specially appointed legal providers and laboratories to expand the availability of its formulations across the United States and the world where legally available.

Dr. Melamede stated, "Cannabis Science is very proud with the release of this second cannabis extract based formulation. Discussions that are going on around the world in the scientific and medical communities as well as conversations with patients all point to a market need for these types of cannabis formulations. We look forward to future releases of more cannabis extract based formulations over the next year as we expand into California, and other States around the United States and the globe where medical cannabis is legal and can be accessed by the patients that need it most."

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

CONTACT:
Cannabis Science Inc.
Robert Kane, 1-561-234-6929
Investor Relations Management
or
Dr. Robert J. Melamede Ph.D., 1-888-889-0888
President & CEO
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com